Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
O
O’Sullivan, Brian
Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Ontario, Canada
(
P 290
)
OSTEOSARCOMA OF THE HEAD AND NECK (HN) IN ADULTS: A CANSARCC STUDY
Brian O’Sullivan
Favorite
O'Brien, Neil
University of California, Los Angeles
(
P 193
)
TARGETING THE PAX-FOXO FUSION VIA HDAC INHIBITION IN RHABDOMYOSARCOMA
Neil O'Brien
Favorite
Ock, Chan-Young
Bang & Ock Consulting Inc
(
P 265
)
DEVELOPMENT OF THERAPEUTIC STRATEGY FOR DESMOID TUMOR WITH NOVEL PATIENT-DERIVED PRECLINICAL MODEL
Chan-Young Ock
Favorite
O'Donnell, Edmond
University of California, Davis
(
P 251
)
TARGETING SOFT TISSUE SARCOMA CANCER STEM CELLS IMPROVES DOXORUBICIN SENSITIVITY IN VITRO
Edmond O'Donnell
Favorite
Oesterheld, Javier
Atrium Health - Levine Children's Hospital
(
P 246
)
PANOBINOSTAT DECREASES DNA DAMAGE REPAIR AND INCREASES SENSITIVITY TO CHEMOTHERAPY IN EWING SARCOMA
Javier Oesterheld
Favorite
Ogawa, Chitose
Department of Pediatric Oncology, National Cancer Center Hospital
(
P 150
)
CLINICAL CHARACTERISTICS OF PRIMARY CUTANEOUS AND SUBCUTANEOUS EWING SARCOMA FAMILY OF TUMORS
Chitose Ogawa
Favorite
Okafor, Chinedu
Duke
(
P 034
)
REGIONAL ANESTHESIA IMPROVES METASTASIS FREE SURVIVAL AFTER SURGICAL RESECTION OF BONE SARCOMAS
Chinedu Okafor
Favorite
Okpara, Chinyere
Eisai Ltd.
(
P 043
)
A MULTICENTER, OPEN-LABEL, RANDOMIZED, PHASE 2 STUDY OF LENVATINIB IN COMBINATION WITH IFOSFAMIDE AND ETOPOSIDE VERSUS IFOSFAMIDE AND ETOPOSIDE IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA
Chinyere Okpara
Favorite
Olimpieri, Pier Paolo
Italian Medicines Agency, Rome, Italy
(
P 162
)
PAZOPANIB IN THE REAL-WORLD SETTING: DATA FROM THE ITALIAN NATIONAL REGISTRY
Pier Paolo Olimpieri
Favorite
Olivares, Vicente
"La Arrixaca" Clinical University Hospital
(
P 078
)
GASTROINTESTINAL STROMAL TUMOURS (GIST) AND RISK OF SECOND NEOPLASMS. INCIDENCE RATE ANALYSIS
Vicente Olivares
Favorite
Olsen, Mallory
Nationwide Children's Hospital
(
P 027
)
LEPTOMENINGEAL ENHANCEMENT WITH NEUROLOGIC CHANGES IN PEDIATRIC BONE SARCOMA PATIENTS: A DIAGNOSTICAL CHALLENGE
Mallory Olsen
Favorite
Olshinka, Noam
Hadassah university medical center
(
P 054
)
PROGNOSTIC FACTORS AFFECTING SURVIVAL OF PATIENTS WITH PRIMARY MUSCULOSKELETAL SARCOMAS FOLLOWING PULMONARY METASTASECTOMY
Noam Olshinka
Favorite
(
P 308
)
REFERRAL DELAYS OF QUEBEC SARCOMA POPULATION : A PROSPECTIVE COHORT STUDY
Noam Olshinka
Favorite
O'Meara, Elaine
University of Limerick
(
P 235
)
ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Elaine O'Meara
Favorite
Omelchenko, Nadezhda
Sarcoma Oncology Center
(
P 123
)
COMPLETE RESPONSES WITH SAINT PROTOCOL: A PHASE 2 STUDY USING SAFE AMOUNTS OF IPILIMUMAB, NIVOLUMAB, AND TRABECTEDIN IN PREVIOUSLY UNTREATED PATIENTS WITH ADVANCED SOFT TISSUE SARCOMA (NCT03138161)
Nadezhda Omelchenko
Favorite
(
P 133
)
PHASE 2 COMBINATION REGIMEN WITH TALIMOGENE LAHERPAREPVEC (TVEC), NIVOLUMAB AND TRABECTEDIN FOR ADVANCED LEIOMYOSARCOMA [NCT# 03886311]
Nadezhda Omelchenko
Favorite
(
P 138
)
SUSTAINED REMISSION/DISEASE CONTROL USING AUTOLOGOUS ENHANCED NATURAL KILLER CELLS PLUS AN IMMUNE CHECKPOINT INHIBITOR AS TREATMENT FOR RARE CHEMOTHERAPY-RESISTANT ADVANCED SOFT TISSUE SARCOMAS
Nadezhda Omelchenko
Favorite
O'Neill, Brianne
Inhibrx, Inc
(
P 041
)
UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
Brianne O'Neill
Favorite
Orbach, Daniel
SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie and Paris Sciences et Lettres
(
P 270
)
ORAL VINORELBINE ACTIVITY FOR PROGRESSIVE DESMOID FIBROMATOSIS TUMOURS IN YOUNG PATIENTS
Daniel Orbach
Favorite
Ordaz, Angel
University of California, San Diego
(
P 279
)
CEMENT AUGMENTATION WITH CEPHALLOMEDUALLARY FIXATION OF PRIMARY AND METASTATIC LESIONS OF THE PROXIMAL FEMUR.
Angel Ordaz
Favorite
Orejana-Martín, Inmaculada
Department of Medical Oncology, Ramón y Cajal University Hospital
(
P 157
)
MOLECULAR SCREENING OF ADVANCED SARCOMAS THROUGH NEXT-GENERATION SEQUENCING IN A TERTIARY UNIVERSITY HOSPITAL
Inmaculada Orejana-Martín
Favorite
Oren Nash, Josh
The Hospital for Sick Children
(
P 191
)
SYNERGISTIC ACTIVITY OF PARP INHIBITORS IN COMBINATION WITH STANDARD CHEMOTHERAPY IN LEIOMYOSARCOMA
Josh Oren Nash
Favorite
Ortiz, Sergio
Hospital general alicante
(
P 119
)
SURGICAL MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOURS SARCOMATOSIS (GISTOSIS). A RETROSPECTIVE MULTI-INSTITUTIONAL STUDY
Sergio Ortiz
Favorite
Ostrow, Gigi
Children's Hospital Los Angeles
(
P 045
)
DETECTION OF CELL-FREE TUMOR DNA IN PATIENTS WITH NEWLY DIAGNOSED PEDIATRIC BONE AND SOFT TISSUE SARCOMAS
Gigi Ostrow
Favorite
O'Sullivan, Maureen
Children's Health Ireland at Crumlin & Trinity College Dublin
(
P 235
)
ELUCIDATING THE ONCOGENIC EFFECT OF BCOR-ITD IN SARCOMA
Maureen O'Sullivan
Favorite
Oton, Ana
SpringWorks Therapeutics
(
P 260
)
BURDEN OF ILLNESS OF DESMOID TUMORS
Ana Oton
Favorite
Ou, Wen-Bin
Brigham and Women’s Hospital
(
P 099
)
CONCURRENT INHIBITION OF CDK2 ADDS TO THE ANTI-TUMOR ACTIVITY OF CDK4/6 INHIBITION IN GIST
Wen-Bin Ou
Favorite
Owen, Dawn
Mayo Clinic
(
P 207
)
SPATIALLY FRACTIONATED RADIATION THERAPY IN SARCOMAS: THE MAYO CLINIC EXPERIENCE
Dawn Owen
Favorite
Owen, Grant
Rush University Medical Center
(
P 086
)
RADIOTHERAPY, VOLUME REDUCTION, AND SHORT-TERM SURGICAL OUTCOMES IN THE TREATMENT OF LARGE MYXOID LIPOSARCOMAS
Grant Owen
Favorite
Back to Top
